Chong Yu to Cisplatin
This is a "connection" page, showing publications Chong Yu has written about Cisplatin.
Connection Strength
0.037
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
Score: 0.037
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.